PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.54%
Negative revenue growth while MCHP stands at 4.92%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.90%
Negative gross profit growth while MCHP is at 5.88%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.53%
Negative EBIT growth while MCHP is at 12.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-38.53%
Negative operating income growth while MCHP is at 12.67%. Joel Greenblatt would press for urgent turnaround measures.
-413.30%
Negative net income growth while MCHP stands at 11.62%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-427.27%
Negative EPS growth while MCHP is at 9.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-427.27%
Negative diluted EPS growth while MCHP is at 15.34%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-4.63%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-4.63%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
3.93%
Dividend growth of 3.93% while MCHP is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
31.68%
OCF growth above 1.5x MCHP's 17.32%. David Dodd would confirm a clear edge in underlying cash generation.
71.62%
FCF growth above 1.5x MCHP's 13.20%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-5.13%
Negative 10Y revenue/share CAGR while MCHP stands at 215.53%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-15.47%
Negative 5Y CAGR while MCHP stands at 51.29%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-15.91%
Negative 3Y CAGR while MCHP stands at 23.39%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
85.67%
10Y OCF/share CAGR under 50% of MCHP's 542.80%. Michael Burry would worry about a persistent underperformance in cash creation.
50.12%
Below 50% of MCHP's 128.76%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-19.16%
Negative 3Y OCF/share CAGR while MCHP stands at 77.13%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-771.93%
Negative 10Y net income/share CAGR while MCHP is at 226.75%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-97.66%
Negative 5Y net income/share CAGR while MCHP is 50.99%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-236.55%
Negative 3Y CAGR while MCHP is 1084.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
384.28%
Below 50% of MCHP's 963.73%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
73.59%
Below 50% of MCHP's 222.96%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
22.61%
Below 50% of MCHP's 156.09%. Michael Burry suspects a serious short-term disadvantage in building book value.
31.76%
Dividend/share CAGR of 31.76% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
1.27%
Dividend/share CAGR of 1.27% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
11.94%
3Y dividend/share CAGR of 11.94% while MCHP is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-19.03%
Firm’s AR is declining while MCHP shows 25.19%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.01%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.48%
Negative asset growth while MCHP invests at 4.51%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.47%
1.25-1.5x MCHP's 1.21%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-0.72%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.80%
We cut SG&A while MCHP invests at 6.39%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.